Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.

SARS-CoV-2 allele-specific probe PCR diagnostics next-generation sequencing variant identification variants of concern

Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
20 04 2022
Historique:
pubmed: 25 3 2022
medline: 23 4 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

Tools to detect SARS-CoV-2 variants of concern and track the ongoing evolution of the virus are necessary to support public health efforts and the design and evaluation of novel COVID-19 therapeutics and vaccines. Although next-generation sequencing (NGS) has been adopted as the gold standard method for discriminating SARS-CoV-2 lineages, alternative methods may be required when processing samples with low viral loads or low RNA quality. To this aim, an allele-specific probe PCR (ASP-PCR) targeting lineage-specific single nucleotide polymorphisms (SNPs) was developed and used to screen 1,082 samples from two clinical trials in the United Kingdom and Brazil. Probit regression models were developed to compare ASP-PCR performance against 1,771 NGS results for the same cohorts. Individual SNPs were shown to readily identify specific variants of concern. ASP-PCR was shown to discriminate SARS-CoV-2 lineages with a higher likelihood than NGS over a wide range of viral loads. The comparative advantage for ASP-PCR over NGS was most pronounced in samples with cycle threshold (

Identifiants

pubmed: 35321556
doi: 10.1128/jcm.02283-21
pmc: PMC9020347
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0228321

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : CIHR
ID : 447335
Pays : Canada
Organisme : CIHR
ID : 158584
Pays : Canada

Références

JAMA. 2021 Nov 02;326(17):1690-1702
pubmed: 34606578
Gene. 1994 Mar 11;140(1):1-5
pubmed: 8125324
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Nat Commun. 2021 Oct 6;12(1):5861
pubmed: 34615860
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Ann Am Thorac Soc. 2020 Jul;17(7):879-891
pubmed: 32267771
Science. 2021 Apr 16;372(6539):
pubmed: 33688063
Brief Bioinform. 2021 Mar 22;22(2):616-630
pubmed: 33279989
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
JMIR Public Health Surveill. 2021 Jun 3;7(6):e28265
pubmed: 33999831
PLoS One. 2021 Feb 24;16(2):e0243185
pubmed: 33626040
Nucleic Acids Res. 2001 Jun 1;29(11):2377-81
pubmed: 11376156
Genome Med. 2020 Jun 30;12(1):57
pubmed: 32605661
PLoS Biol. 2021 May 7;19(5):e3001236
pubmed: 33961632
PLoS One. 2020 Dec 31;15(12):e0244777
pubmed: 33382805
Nat Rev Genet. 2021 Dec;22(12):757-773
pubmed: 34535792
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
J Virol. 2021 Mar 1;:
pubmed: 33649194
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
J Infect Dis. 2021 Aug 16;224(4):595-605
pubmed: 34031695
J Clin Microbiol. 2021 Nov 18;59(12):e0144621
pubmed: 34432488
J Mol Diagn. 2010 Jan;12(1):109-17
pubmed: 19948821

Auteurs

Jeremy Ratcliff (J)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

Farah Al-Beidh (F)

Imperial College London, London, United Kingdom.
Imperial College Health NHS Trust, St. Mary's Hospital, London, United Kingdom.

Sagida Bibi (S)

Oxford Vaccine Group, Department of Paediatrics, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

David Bonsall (D)

Big Data Institute, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

Sue Ann Costa Clemens (SA)

Oxford Vaccine Group, Department of Paediatrics, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Institute for Global Health, University of Siena, Siena, Italy.

Lise Estcourt (L)

Haematology Theme, Radcliffe Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Clinical Trials Unit, NHS Blood and Transport, Oxford, United Kingdom.

Amy Evans (A)

Clinical Trials Unit, NHS Blood and Transport, Oxford, United Kingdom.

Matthew Fish (M)

School of Immunology and Microbial Sciences, Kings College London, London, United Kingdom.
Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, London, United Kingdom.
Centre for Inflammation Research, The University of Edinburghgrid.4305.2, Edinburgh, United Kingdom.

Pedro M Folegatti (PM)

Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

Anthony C Gordon (AC)

Imperial College London, London, United Kingdom.
Imperial College Health NHS Trust, St. Mary's Hospital, London, United Kingdom.

Cecilia Jay (C)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

Aislinn Jennings (A)

School of Immunology and Microbial Sciences, Kings College London, London, United Kingdom.
Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, London, United Kingdom.
Centre for Inflammation Research, The University of Edinburghgrid.4305.2, Edinburgh, United Kingdom.

Emma Laing (E)

Clinical Trials Unit, NHS Blood and Transport, Oxford, United Kingdom.

Teresa Lambe (T)

Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

George MacIntyre-Cockett (G)

Big Data Institute, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

David Menon (D)

University Division of Anaesthesia, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.

Paul R Mouncey (PR)

Intensive Care National Audit and Research Centre, London, United Kingdom.

Dung Nguyen (D)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

Andrew J Pollard (AJ)

Oxford Vaccine Group, Department of Paediatrics, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.

Maheshi N Ramasamy (MN)

Oxford Vaccine Group, Department of Paediatrics, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

David J Roberts (DJ)

Haematology Theme, Radcliffe Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Clinical, Research, and Development, NHS Blood and Transport, Oxford, United Kingdom.

Kathryn M Rowan (KM)

Intensive Care National Audit and Research Centre, London, United Kingdom.

Jennifer Rynne (J)

School of Immunology and Microbial Sciences, Kings College London, London, United Kingdom.
Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, London, United Kingdom.
Centre for Inflammation Research, The University of Edinburghgrid.4305.2, Edinburgh, United Kingdom.

Manu Shankar-Hari (M)

School of Immunology and Microbial Sciences, Kings College London, London, United Kingdom.
Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, London, United Kingdom.
Centre for Inflammation Research, The University of Edinburghgrid.4305.2, Edinburgh, United Kingdom.

Sarah Williams (S)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Heli Harvala (H)

Microbiology Services, NHS Blood and Transport, London, United Kingdom.

Tanya Golubchik (T)

Big Data Institute, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

Peter Simmonds (P)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH